WBB Pounds the Table on Omeros Following Orphan Drug Status, Maintains Strong Buy Rating, $20 Target

WBB Securities maintains Omeros Corporation (NASDAQ: OMER ) with a Strong Buy and maintains $20.00 PT. The firm's Stephen Brozak said, "As large pharmaceutical companies see their pipelines dwindling, they will need to turn to smaller companies with proprietary molecules that can be developed into new therapeutic capabilities. In our opinion, Omeros